## Prof. Mario Roselli Biosketch

Mario Roselli received his M.D. in 1983 at the University of Perugia. Specialist in Oncology (1986 at the University of Rome Tor Vergata) and in Nuclear Medicine (1992 at the University of Naples Federico II), he is currently Head of Medical Oncology of the University Hospital Tor Vergata, Full Professor in Medical Oncology at the Department of Systems Medicine, School of Medicine University of Rome "Tor Vergata", Italy and Head of the Specialization School in Medical Oncology of



the same University. Prof. Roselli is presently member of the Tor Vergata Institutional Review Board (IRB) and participates as Principal Investigator (PI) and/or co-investigator to several clinical projects, sponsored and granted either by Government Institutions or private Companies. Among the funded projects of which Dr. Roselli has been PI, the "MCC - Medical Care Continuity" sponsored by the European Community (2004-2008) is of great interest in the context of the aims and mission pursued in the "continuous care trial" established in the Medical Oncology ward he directs. The project, aimed at establishing a telemedicine network between various European countries (France, Belgium, Italy and Poland) to ensure the continuity of care of cancer outpatients receiving active chemotherapy. Following this experience, in 2009, as the Chief of the Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Prof. Roselli established a collaboration agreement with the San Raffaele Palliative Care Centers. Over this period, an interdisciplinary team has been refined to provide integrated oncologic, medical, and supportive care services for patients with cancer disease and their families, from diagnosis to palliative care. This has been qualified by an ISO 9001-2008 certificate. The entire project has also been rewarded since 2012 with the certificate award for "designated centers of integrated oncology and palliative care by the European Society for Medical Oncology" (www.esmo.org). Prof. Roselli's active involvement in clinical and translational studies has lead to the publication of 246 publications in international peer journals with an H-Index of 43. As part of an active collaboration with the Laboratory of Tumor Immunology and Biology of the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA, Prof. Roselli has been involved in the investigation of novel strategies for cancer vaccines, such as the characterization of the T-box transcription factor Brachyury as a driver of epithelial-to-mesenchimal transition in human carcinoma cells, aiming to the development of Brachyury-based immunotherapeutic approaches for the treatment of cancer. For such collaboration, he has been awarded by the Society for Immunotherapy of Cancer as NCI component of the "2020 SITC TEAM SCIENCE AWARD". Prof. Roselli is member of several national [such as the Italian Society of Immunopharmacology, the Italian Society of Medical Oncology (AIOM), and the Italian Society of Toracic Oncology (AIOT)] and international scientific societies [the European Association for Cancer Research (EACR), the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO)]. He is also member of the Editorial Boards of several Peer-Reviewed Scientific Journals.